Logo image of RSLS

RESHAPE LIFESCIENCES INC (RSLS) Stock Fundamental Analysis

NASDAQ:RSLS - Nasdaq - US76090R3093 - Common Stock - Currency: USD

1.12  -0.11 (-8.94%)

After market: 1.2 +0.08 (+7.14%)

Fundamental Rating

3

RSLS gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 190 industry peers in the Health Care Equipment & Supplies industry. RSLS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, RSLS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year RSLS has reported negative net income.
In the past year RSLS has reported a negative cash flow from operations.
RSLS had negative earnings in each of the past 5 years.
RSLS had a negative operating cash flow in each of the past 5 years.
RSLS Yearly Net Income VS EBIT VS OCF VS FCFRSLS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M

1.2 Ratios

RSLS's Return On Assets of -125.86% is on the low side compared to the rest of the industry. RSLS is outperformed by 88.83% of its industry peers.
The Return On Equity of RSLS (-475.25%) is worse than 87.77% of its industry peers.
Industry RankSector Rank
ROA -125.86%
ROE -475.25%
ROIC N/A
ROA(3y)-213.94%
ROA(5y)-174.81%
ROE(3y)-525.31%
ROE(5y)-397.87%
ROIC(3y)N/A
ROIC(5y)N/A
RSLS Yearly ROA, ROE, ROICRSLS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1K -1K 2K 3K

1.3 Margins

With a decent Gross Margin value of 68.19%, RSLS is doing good in the industry, outperforming 76.60% of the companies in the same industry.
RSLS's Gross Margin has improved in the last couple of years.
RSLS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.19%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.57%
GM growth 5Y9.59%
RSLS Yearly Profit, Operating, Gross MarginsRSLS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

More info and screens

5

2. Health

2.1 Basic Checks

RSLS does not have a ROIC to compare to the WACC, probably because it is not profitable.
RSLS has less shares outstanding than it did 1 year ago.
RSLS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for RSLS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RSLS Yearly Shares OutstandingRSLS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 100K 200K 300K 400K 500K
RSLS Yearly Total Debt VS Total AssetsRSLS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

2.2 Solvency

RSLS has an Altman-Z score of -162.60. This is a bad value and indicates that RSLS is not financially healthy and even has some risk of bankruptcy.
RSLS has a worse Altman-Z score (-162.60) than 93.62% of its industry peers.
RSLS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -162.6
ROIC/WACCN/A
WACC9.14%
RSLS Yearly LT Debt VS Equity VS FCFRSLS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 20M -20M 40M 60M

2.3 Liquidity

RSLS has a Current Ratio of 1.33. This is a normal value and indicates that RSLS is financially healthy and should not expect problems in meeting its short term obligations.
RSLS's Current ratio of 1.33 is on the low side compared to the rest of the industry. RSLS is outperformed by 81.91% of its industry peers.
RSLS has a Quick Ratio of 1.33. This is a bad value and indicates that RSLS is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.60, RSLS is not doing good in the industry: 92.55% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 1.33
Quick Ratio 0.6
RSLS Yearly Current Assets VS Current LiabilitesRSLS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M

More info and screens

4

3. Growth

3.1 Past

RSLS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 95.65%, which is quite impressive.
The Revenue for RSLS has decreased by -16.59% in the past year. This is quite bad
RSLS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.95% yearly.
EPS 1Y (TTM)95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-204.61%
Revenue 1Y (TTM)-16.59%
Revenue growth 3Y76.07%
Revenue growth 5Y-0.95%
Sales Q2Q%6.36%

3.2 Future

The Earnings Per Share is expected to grow by 41.36% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 16.06% on average over the next years. This is quite good.
EPS Next Y99.78%
EPS Next 2Y41.36%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year12.24%
Revenue Next 2Y16.06%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
RSLS Yearly Revenue VS EstimatesRSLS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M
RSLS Yearly EPS VS EstimatesRSLS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20M -40M -60M -80M -100M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RSLS. In the last year negative earnings were reported.
Also next year RSLS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RSLS Price Earnings VS Forward Price EarningsRSLS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RSLS Per share dataRSLS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -50 -100 -150 -200

4.3 Compensation for Growth

RSLS's earnings are expected to grow with 41.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.36%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RSLS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RESHAPE LIFESCIENCES INC

NASDAQ:RSLS (2/21/2025, 8:00:01 PM)

After market: 1.2 +0.08 (+7.14%)

1.12

-0.11 (-8.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)03-31 2025-03-31/amc
Inst Owners81.7%
Inst Owner Change-9.03%
Ins Owners26.67%
Ins Owner Change0%
Market Cap795.20K
Analysts43.33
Price TargetN/A
Short Float %3.47%
Short Ratio0.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-11.59%
Min Revenue beat(2)-12.78%
Max Revenue beat(2)-10.4%
Revenue beat(4)0
Avg Revenue beat(4)-11.15%
Min Revenue beat(4)-12.78%
Max Revenue beat(4)-9.41%
Revenue beat(8)0
Avg Revenue beat(8)-10.55%
Revenue beat(12)0
Avg Revenue beat(12)-14.07%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.1
P/FCF N/A
P/OCF N/A
P/B 0.53
P/tB 0.53
EV/EBITDA N/A
EPS(TTM)-205.92
EYN/A
EPS(NY)-0.37
Fwd EYN/A
FCF(TTM)-8.74
FCFYN/A
OCF(TTM)-8.73
OCFYN/A
SpS11.53
BVpS2.09
TBVpS2.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -125.86%
ROE -475.25%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.19%
FCFM N/A
ROA(3y)-213.94%
ROA(5y)-174.81%
ROE(3y)-525.31%
ROE(5y)-397.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y20.57%
GM growth 5Y9.59%
F-Score5
Asset Turnover1.46
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.33
Quick Ratio 0.6
Altman-Z -162.6
F-Score5
WACC9.14%
ROIC/WACCN/A
Cap/Depr(3y)17.25%
Cap/Depr(5y)28.26%
Cap/Sales(3y)1.41%
Cap/Sales(5y)4.14%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)95.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-204.61%
EPS Next Y99.78%
EPS Next 2Y41.36%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-16.59%
Revenue growth 3Y76.07%
Revenue growth 5Y-0.95%
Sales Q2Q%6.36%
Revenue Next Year12.24%
Revenue Next 2Y16.06%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y54.61%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y72.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y72.44%
OCF growth 3YN/A
OCF growth 5YN/A